Article Data

  • Views 696
  • Dowloads 141

Original Research

Open Access

Atypical medullary breast carcinoma – the clinical picture and prognosis

  • B. Sas-Korczynska1,*,
  • J. Jakubowic1
  • J. Rys3
  • J.W. Mitus2
  • P. Skotnicki2
  • XXX1
  • T. Walasek4
  • M. Reinfuss4

1Department of Clinical Oncology, Poland

2Departmet of Surgical Oncology, Poland

3Departmet of Pathology, Poland

4Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Krakow (Poland)

DOI: 10.12892/ejgo3610.2018 Vol.39,Issue 1,February 2018 pp.32-36

Published: 10 February 2018

*Corresponding Author(s): B. Sas-Korczynska E-mail: z5korczy@cyf-kr.edu.pl

Abstract

Purpose: The purpose of this paper was to present the clinical picture and the effectiveness of treatment patients with atypical medullary breast carcinoma (A-MBC). Materials and Methods: Sixty-five patients with A-MBC were treated between 1975 and 2005. More of them (70.2%) were in Stage I or II and had no expression of c-erb-B2 gene (81.5%), estrogen receptor (87.7%), and progesterone receptor (76.9%). Radical mastectomy was applied in 55 patients (84.6%) and remaining ten (15.4%) patients underwent breast conserving therapy. The treatment effectiveness was evaluated as ten-year disease-free survival (DFS) rate (Kaplan-Meier method). Results: The ten-year disease-free survival (DFS) rate was 61.5%. Only lymph nodal status was statistically significant prognostic factor. Ten–year DFS rate was 82.1% and 30.8% for pN0 and pN+, respectively. Conclusion: Although A-MBC has probably a slightly better- prognosis than invasive ductal breast carcinoma, these patients should be treated according to the same rules as those with breast cancer of basal-like or triple-negative type.

Keywords

Medullary breast cancer; Atypical medullary breast cancer; Triple-negative breast cancer.

Cite and Share

B. Sas-Korczynska,J. Jakubowic,J. Rys,J.W. Mitus,P. Skotnicki,XXX,T. Walasek,M. Reinfuss. Atypical medullary breast carcinoma – the clinical picture and prognosis. European Journal of Gynaecological Oncology. 2018. 39(1);32-36.

References

1] Weigelt B., Geyer F.C., Reis-Filho J.S.: “Histological types of breast cancer: how special are they?” Mol. Oncol., 2010, 4, 192.

[2] Bertucci F., Finetti P., Cervera N, Charafe-Juffret E, Mamessier E, Adelaide J.. et al.: “Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers”. Cancer Res., 2006, 66, 4636.

[3] Jensen M.L., Kiaer H., Andersen J., Jensen V., Melsen F. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology, 1997, 30, 523.

[4] Rakha E.A., Reis-Filho J.S., Ellis I.O.: “Basal-like breast cancer: acritical review”. J. Clin. Oncol., 2008, 26, 2568.

[5] Marginean F., Rakha E.A., Ho B.C, Ellis I.o, Lee A.H.: “Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast”. Mod. Pathol., 2010, 23, 1357.

[6] Jacquemier J., Reis-Filho J.S., Lakhani S.R., Rakha E.: “Carcinomas with medullary features. WHO classification of tumours of the breast”. 4th ed. Lyon: International Agency for Research on Cancer, 2012, 46.

[7] Vargas A.C., Da Silva L., Lakhani S.R.: “The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers”. Fam. Cancer, 2010, 9, 545.

[8] Kleer C.G.: “Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions”. Arch. Pathol. Lab. Med., 2009, 133, 1822.

[9] Lakhani S.R., Van De Vijver M.J., Jacquemier J.: “The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER 2, and p53 in patients with mutations in BRCA1 and BRCA2”. J. Clin. Oncol., 2002, 20, 2310.

[10] Jacquemier J., Padovani L., Rabayrol L., Lakhani S.R., Penault- Llorca F., Denoux Y., et al.: “Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005,207,260-268.

[11] Rakha E.A., Ellis I.O. Triple-negative/basal-like breast cancer: review”. Pathology, 2009, 41, 40.

[12] Vu-Nishino H., Tavassoli F.A., Ahrens W.A., Haffty B.G.: “Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT)”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 1040.

[13] Ridolfi R.L., Rosen P.P., Port A., Kinne D., Miké V.: “Medullary carcinoma of the breast: a clinicopathologic study with 10 year followup”. Cancer, 1977, 40, 1365.

[14] Gaffey M.J., Mills S.E., Frierson H.F.Jr., Zarbo R.J., Boyd J.C., Simpson J.F., Weiss L.M.: “Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis”. Mod. Pathol., 1995, 8, 31.

[15] Rigaud C., Theobald S., Noël P., Badreddine J., Barlier C., Delobelle A., et al.: “Medullary carcinoma of the breast. A multicenter study of its diagnostic consistency”. Arch. Pathol. Lab. Med., 1993, 117, 1005.

[16] Pedersen L., Holck S., Schiødt T., Zedeler K., Mouridsen H.T.: “Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications”. Breast Cancer Res. Treat., 1989, 14, 91.

[17] Rakha E.A., Aleskandarany M., El-Sayed M.E., Blamey R.W., Elston C.W.: “The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast”. Eur. J. Cancer, 2009, 5, 1780.

[18] Wargotz E.S., Silverberg S.G.: “Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria”. Hum. Pathol., 1988, 19, 1340.

[19] Rapin V., Contesso G., Mouriesse H., Bertin F., Lacombe M.J., Piekarski J.D., et al.: “Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma”. Cancer, 1988, 61, 2503.

[20] Fisher E.R., Kenny J.P., Sass R., Dimitrov N.V., Siderits R.H., Fisher B.: “Medullary cancer of the breast revisited”. Breast Cancer Res. Treat., 1990, 16, 215.

[21] Xu R., Feiner H., Li P., Yee H., Inghirami G., Delgado Y., Perle M.A.: “Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast”. Arch. Pathol. Lab. Med., 2003, 127, 1458.

[22] Vong J.S., Yu A.M., Ng D.C.H., Lui P.C.W., Law B.K.B., Chau H.H.L., et al.: “Reduced numbers of regulatory T cells in breast carcinoma with medullary features”. Histopathology. 2011,59,345-349

[23] Kroupis C., Lianidou E., Goutas N., Ladopoulou A., Konstantopoulou I., Pantazidis A., et al.: “Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation”. Breast J., 2003, 9, 260.

[24] Matkovic B., Juretic A., Separovic V., Novosel I., Separovic R., Gamulin M., Kruslin B.: “Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer”. Tumori, 2008, 94, 838.

[25] Shousha S.: “Medullary carcinoma of the breast and BRCA1 mutation”. Histopathology, 2000, 37, 182.

[26] Zhang J., Wang Y., Yin Q., Zhang W., Zhang T., Niu Y.: “An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy”. Int. J. Clin. Exp. Pathol., 2013, 6, 1380.

[27] Rodríguez-Pinilla S.M., Rodríguez-Gil Y., Moreno-Bueno G., Sarrió D., Martín-Guijarro M.C., Hernandez L., Palacios J.: “Sporadic invasive breast carcinomas with medullary features display a basallike phenotype: an immunohistochemical and gene amplification study”. Am. J. Surg. Pathol., 2007, 31, 501.

[28] Reinfuss M., Stelmach A., Mituś J., Ryś J., Duda K.: “Typical medullary carcinoma of the breast. A clinical and pathological analysis of 52 cases”. J. Surg. Oncol., 1995, 60, 89.

[29] Ashida A., Fukutomi T., Tsuda H., Akashi-Tanaka S., Ushijima T.: “Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation”. Jpn. J. Clin. Oncol., 2000, 30, 30.

[30] Marcus J.N., Watson P., Page D.L., Narod S.A., Lenoir G.M., Tonin P., et al.: “Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage”. Cancer, 1996, 77, 697.

[31] Tamiolakis D., Simopoulos C., Cheva A., Lambropoulou M., Kotini A., Jivannakis T., Papadopoulos N.: “Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast”. Eur. J. Gynaecol. Oncol., 2002, 23, 433.

[32] Nurlaila I., Telisinghe P.U., Ramasamy R.: “CD8+ lymphocytes and apoptosis in typical and atypical medullary carcinomas of the breast”. Immunol. Lett., 2013, 156, 123.

[33] Chu Z., Lin H., Liang X, Huang R, Zhan Q, Jiang J, Zhou X.: “Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases”. PLOS One, 2014, 9, e111493.

[34] Cheung Y.C., Chen S.C., Lee K.F., Wan Y.L., Ng S.H.: “Sonographic and pathologic findings in typical and atypical medullary carcinomas of the breast”. J. Clin. Ultrasound, 2000, 28, 325.

[35] Yilmaz E., Lebe B., Balci P., Sal S., Canda T.: “Comparison of mammographic and sonographic findings in typical and atypical medullary carcinomas of the breast”. Clin. Radiol., 2002, 57, 640.

[36] Kaplan E.L., Meier P.: “Nonparametric estimation from incomplete observation”. J. Am. Stat. Assoc., 1958, 53, 457

[37] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al.: “Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples”. Br. J. Cancer, 1977, 35, 1.

[38] Cox D.R.: “Regression models and life-tables”. J. R. Stat. Soc. Series B. Stat Methodol., 1972, 34, 187.

[39] Rubens J.R., Lewandrowski K.B., Kopans D.B., Koerner F.C., Hall D.A., McCarthy K.A.: “Medullary carcinoma of the breast. Overdiagnosis of a prognostically favorable neoplasm”. Arch. Surg.,1990, 125, 601.

[40] Lim K.H.J., Telisinghe P.U., Abdullah M.S., Ramasamy R.: “Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast”. Cancer Immunity, 2010, 10, 3.

[41] Orlando L., Renne G., Rocca A., Curigliano G., Colleoni M., Severi G., et al.: “Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype”. Ann. Oncol., 2005, 16, 1094.

[42] Sobrino-Mota V., Lagarejos-Bernardo S., Varela-Mezquita B., Castro Y., Segura-González C., Pérez-Milán F.: “Unusual sonographic findings in a case of atypical medullary inflammatory carcinoma of the breast”. J. Clin. Ultrasound, 2008, 36, 166.

[43] Jin B., Liu Y.P., Wang H.J., Wang Q.S.: “Gastric metastasis of atypical medullary carcinoma from breast: a case report”. Chin. Med. Sci J., 2012, 27, 121.

[44] McCarty M.J., Vukelja S.J.: “Atypical medullary carcinoma of the breast metastatic to the oral cavity”. Am. J. Otolaryngol., 1994, 15, 189.

[45] Jacquemier J., Robert-Vague D., Torrente M., Lieutaud R.: “Mise enm evidence des immunoglobulines lymphoplasmocytaires et epitheliales dans les carcinomes infiltrans á stroma lymphoide et les carcinomes médullaires du sein”. Arch. Anat. Cycol. Path., 1983, 31, 296.

[46] Harris M. Lessells A.M.: “The ultrastructure of medullary, atypical medullary and non-medullary carcinomas of the breast”. Histopathology, 1986, 10, 405.

[47] Cao A.Y, He M., Huang L., Shao Z.M., Di G.M.: “Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified”. World J. Surg. Oncol., 2013, 11, 91.

[48] Zhang J., Wang Y., Yin Q., Zhang W., Zhang T., Niu Y.: “An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy”. Int. J. Clin. Exp. Pathol., 2013, 6, 1380.

[49] Flucke U., Flucke M.T., Hoy L., Breuer E., Goebbels R., Rhiem K., et al.: “Distinguishing medullary carcinoma of the breast from highgrade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach”. Histopathology, 2010, 56, 852.

[50] Thurman S.A., Schnitt S.J., Connolly J.L., Gelamn R., Silver B., Harris J.R, Recht A.: “Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59, 152.

[51] Pedersen L., Zedeler K., Holck S, Schiodt T, Mouridsen H.T.: “Medullary carcinoma of the breast, proposal for a new simplified histopathological definition”. Br. J. Cancer, 1991, 63, 591.

[52] Tavassoli F.A.: “Infiltrating carcinomas, common and familiar special types: medullary carcinoma”. In: Tavassoli F.A. (ed). Pathology of the breast. Norwalk, Connecticut: Appleton and Lange, 1992, 333.

[53] Pedersen L., Zedeler K., Holck S., Schiodt T., Mouridsen H.T.:m “Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer”. Eur. J. Cancer, 1995, 31A, 2289.

[54] Ponsky J.L., Gliga L., Reynolds S.: “Medullary carcinoma of the breast: an association with negative hormonal receptors”. J. Surg. Oncol., 1984, 25, 76.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top